BRSR for Pharma — Material Disclosures, API Water Intensity, and the CDSCO + USFDA Regulatory Overlay

Why this guide exists

Indian listed pharma entities sit at a distinctive intersection within the Top 1,000 listed-entity cohort by market capitalisation — combining chemical-process manufacturing (API plants), light secondary manufacturing (formulation + packaging), heavily regulated waste streams (biomedical + pharmaceutical), and a parallel layer of product-quality regulation (CDSCO domestically, USFDA / EMA / WHO PQ for exporters).

This guide walks through the BRSR-specific patterns observed for Indian listed pharma entities — the Core attributes that tend to be most material in practice, the API vs formulation environmental-profile distinction, the water-intensity and biomedical-waste reporting, the regulatory overlay with CDSCO and USFDA, and how the BRSR submission interacts with the product-quality regulators that already govern pharma operations.

This guide describes common BRSR disclosure patterns for the pharma sector, but entity-level materiality, current SEBI phase-in applicability, and the assurance standard applied should always be confirmed for the specific listed entity.

The pharma profile within the Top 1,000

Common sectoral features observed in Indian listed pharma BRSR disclosures (these shape the disclosure profile in practice but are not a SEBI-prescribed sector taxonomy):

• NIC classification — Pharma manufacturers are typically classified under NIC 21 (Manufacture of pharmaceuticals, medicinal chemical, and botanical products). Where the entity also has a substantial chemical-intermediates business, NIC 20 (Chemicals and chemical products) may appear alongside.
• Hybrid plant footprint — Many listed pharma entities operate a mix of API (Active Pharmaceutical Ingredient) synthesis plants, formulation / packaging units, and increasingly contract development and manufacturing (CDMO / CRAMS) sites. The environmental profile differs materially across these — API plants are heavy on Scope 1 (steam, reactor heating, solvent recovery, fugitive VOC) and water; formulation plants are dominated by Scope 2 electricity for blending, compression, coating, packaging, and clean-room HVAC.
• Geographic concentration in non-metro clusters — Indian pharma manufacturing is concentrated in industrial clusters in Andhra Pradesh / Telangana (the Hyderabad pharma corridor), Gujarat (Ankleshwar, Vapi, Ahmedabad), Himachal Pradesh (Baddi), and Sikkim, often in Tier 2 / Tier 3 locations. Job Creation in Smaller Towns under Principle 8 is therefore frequently a positive disclosure.
• Substantial R&D footprint — Listed pharma entities allocate a meaningful share of revenue to R&D (formulation development, generic ANDA filings, biosimilars, novel drug discovery). The R&D workforce shifts the entity’s workforce mix toward higher-skill cohorts and often improves gender-diversity ratios at the corporate level.
• Regulated waste streams — Pharma operations generate biomedical waste, hazardous chemical waste (spent solvents, off-spec product, sludges), and multi-layered plastic packaging — each governed by distinct compliance regimes outside of BRSR but feeding the same Principle 6 disclosure.
• Parallel product-quality regime — CDSCO domestically; USFDA / EMA / WHO PQ for exporters; state-level Drug Control Administration and Pollution Control Board oversight. None of these substitute for SEBI BRSR Core, but the data they generate flows into BRSR disclosures.

Material BRSR Core attributes for pharma

The BRSR Core (per SEBI/HO/CFD/CFD-SEC-2/P/CIR/2023/122 dated 12 July 2023) is structured around 9 ESG attributes. The materiality of each attribute for a pharma entity is entity-specific, but the patterns commonly observed in published submissions are:

BRSR Core attribute	NGRBC Principle	Typical materiality for pharma	Sector notes
GHG emission intensity per revenue (Scope 1 + 2)	P6	Frequently substantive to high for entities with material API capacity	Driven by steam generation, reactor heating, solvent-recovery thermal load, fugitive VOC, and facility HVAC. See GHG emission intensity per revenue.
Water withdrawal intensity	P6	Frequently material for entities with API operations	API synthesis is water-intensive; ETP performance and ZLD status commonly disclosed. See Water withdrawal intensity.
Job creation in smaller towns	P8	Typically substantive for entities with Tier 2 / Tier 3 plant locations	Hyderabad corridor, Baddi, Vapi, Sikkim clusters frequently feature. See Job creation in smaller towns.
Openness of business (related-party transactions)	P1	Typically moderate; can be material for entities with extensive captive supply or overseas subsidiary structures	Inter-group API supply, CDMO arrangements, captive marketing affiliates feature. See Openness of business.
Gross wages paid to women	P5	Typically substantive disclosure	Pharma R&D workforce often has higher gender diversity than process-manufacturing peers. See Female wages disclosure.
Spend on wellbeing	P3	Typically moderate to substantive	Health insurance, occupational health surveillance (especially around solvent / API exposure), parental leave are usually well-funded. See Spend on wellbeing.
Complaints disclosure (POSH)	P5	Typically substantive disclosure given workforce size	See POSH complaints disclosure.

The materiality column reflects patterns observed in published Indian pharma BRSR submissions — entity-level materiality assessment is the framework that should drive actual reporting emphasis. See the Materiality Assessment Walkthrough.

Sector-specific patterns by area

API vs formulation distinction

Many listed pharma entities operate both API plants and formulation plants under the same listed entity. The environmental profile differs materially:

• API plants (chemical-intermediate synthesis) — Scope 1 dominated by steam, reactor heating, solvent-recovery thermal load, and fugitive VOC emissions. Water withdrawal is substantial. Effluent profile is complex (high COD, dissolved solids, sometimes salinity); ETP + RO + ZLD installations are common.
• Formulation plants (dosage-form manufacturing) — Scope 2 dominated, driven by electricity for blending, granulation, compression, coating, packaging, and HVAC for clean-room classification (ISO Class 7 / 8 / 9). Water use is lower and primarily for utility + cleaning.

For BRSR intensity reporting at the consolidated listed-entity level, the API : formulation revenue mix substantially shifts where the entity falls on emission and water-intensity benchmarks against listed pharma peers. Many entities provide a narrative split (per-segment intensity) to contextualise the aggregate numbers — not a SEBI prescription, just an observed pattern that improves comparability.

For entities with significant contract manufacturing (CDMO / CRAMS) operations, the boundary basis applied for BRSR scope (operational control, financial control, equity-share) should be applied consistently with the GHG Protocol Corporate Standard and the methodology guidance in the SEBI December 2024 Industry Standards on BRSR Core.

Water intensity in API plants

For listed pharma entities with material API operations, Water Withdrawal Intensity is frequently observed as a material Core attribute. API synthesis uses water as solvent, as cooling medium, and for equipment cleaning. Common features of pharma BRSR water disclosures:

• Effluent Treatment Plant (ETP) + Reverse Osmosis (RO) capacity disclosed in Principle 6 narrative
• Zero Liquid Discharge (ZLD) status at the plant level — increasingly required by State Pollution Control Boards for pharma clusters in water-stressed regions
• Water recycled / reused as % of total withdrawn — commonly disclosed even though it is not a BRSR Core line item, because peer-benchmarking practice has anchored on it
• Source mix — surface, ground, third-party, sea-water, others — relevant under the 5 source categories of the BRSR water-withdrawal disclosure

Process emissions in API

Scope 1 for an API plant is meaningfully more complex than for formulation:

• Steam generation — typically from natural-gas or coal-fired boilers; CO₂, methane, and N₂O are all relevant
• Reactor heating — direct gas firing or indirect via thermal-oil systems
• Solvent recovery — energy-intensive distillation columns and incinerators for unrecoverable solvents
• Fugitive VOC emissions — solvent losses across handling, storage, charging, and process operations; tracked under environmental clearance conditions and reflected in Principle 6 narrative
• Standby DG sets — facility-resilience requirement, contributes to Scope 1 fuel consumption

Quantification methodology should be documented as part of the assurance preparation — see the Document and Evidence Requirements guide. The current EU Carbon Border Adjustment Mechanism (CBAM) scope (Regulation (EU) 2023/956) covers steel, cement, aluminium, fertilizers, hydrogen, and electricity — not pharmaceutical chemicals — so CBAM is not a present-day pharma reporting requirement, but the Scope 1 carbon-accounting discipline carries over to any future scope expansion.

R&D spend treatment

Pharma R&D spend is substantial and typically disclosed in Section A under capital and revenue expenditure. Within BRSR narrative:

• Principle 2 (Sustainable Products) is the natural home for R&D narrative tied to green chemistry, solvent substitution, process-mass-intensity reduction, or accessibility / affordability outcomes (generics for low-income markets, biosimilars).
• Principle 9 (Customer Value) absorbs R&D narrative tied to product safety, post-marketing surveillance, and pharmacovigilance.

The Income Tax treatment of R&D spend (historically Section 35(2AB) weighted deduction, progressively scaled down by recent Finance Acts) does not influence BRSR classification — BRSR captures the spend and its orientation regardless of tax treatment.

Biomedical waste + EPR for pharma packaging

Pharma waste reporting spans multiple compliance regimes that all feed Principle 6:

• Biomedical waste under the Bio-Medical Waste Management Rules 2016 (and 2018, 2019 amendments) — categorised by colour code (yellow / red / white / blue) and tracked through Common Biomedical Waste Treatment Facilities (CBWTFs). Pharma manufacturers generate biomedical waste from R&D / QC laboratories, clinical-trial facilities, and from administered-product disposal.
• Hazardous chemical waste under the Hazardous and Other Wastes (Management and Transboundary Movement) Rules 2016 — spent solvents, ETP / WWTP sludges, off-spec product, distillation residues.
• Plastic packaging waste under EPR — multi-layered plastics (blister packs), secondary cartons, and tertiary packaging are reportable under the Plastic Waste Management Rules 2016 and the Extended Producer Responsibility (EPR) Guidelines (2022, 2024 amendments). Pharma brand-owners register on the CPCB EPR portal and procure recycling certificates against introduced volumes. EPR-portal volumes and BRSR Principle 6 narrative on plastic packaging should reconcile — divergence is a common assurance finding.

Regulatory overlay — CDSCO + USFDA + Indian Pharmacopoeia

The pharma sector operates under an extensive product-quality and safety regime that runs in parallel with (not replacing) SEBI BRSR:

• CDSCO — Central Drugs Standard Control Organisation regulates drug approvals, GMP compliance under Schedule M of the Drugs and Cosmetics Rules 1945, and pharmacovigilance.
• USFDA — for entities exporting to the US market, regulates manufacturing facilities under 21 CFR cGMP. Form 483 observations, warning letters, and import alerts are public regulatory actions that may need narrative reflection in BRSR Principle 9.
• EMA / WHO PQ — analogous regimes for EU and WHO-procurement export markets.
• Indian Pharmacopoeia Commission — sets monograph standards for drugs marketed in India.

None of these substitute for SEBI BRSR Core. They do generate underlying data (facility audits, deviation reports, recalls, complaints) that flows into BRSR Principle 9 (Customer Value) and, where employee health is affected, Principle 3 narrative.

Common Scope 3 categories for the sector

Comprehensive Scope 3 disclosure historically sat in Principle 6 Leadership (voluntary), but per the SEBI BRSR Core circular dated 12 July 2023, Scope 3 GHG disclosure is required from the top 250 listed entities on a comply-or-explain basis from FY 2024–25, with assurance phased from FY 2025–26 on the same basis. Value Chain ESG disclosures (covering top upstream and downstream partners cumulatively to 75% of purchases / sales by value) apply on the same comply-or-explain basis. See the Value Chain Disclosure glossary entry.

Scope 3 categories commonly observed as material in published pharma submissions:

• Category 1 (Purchased goods and services) — APIs and intermediates from third-party manufacturers (often imported from China + Italy), excipients, packaging materials. Frequently the largest Scope 3 category for entities reliant on imported Key Starting Materials.
• Category 4 (Upstream transportation and distribution) — including cold-chain logistics for biologics and vaccines.
• Category 11 (Use of sold products) — applicable in specific cases such as metered-dose inhalers using HFC propellants, which release GHG on actuation.
• Category 12 (End-of-life treatment of sold products) — disposal of unused medication and pharmaceutical packaging at the end of consumer use.

For methodology depth on Scope 3 calculation conventions, see the Scope 3 for Service Companies guide — the conventions translate to pharma’s non-Cat-1 / non-Cat-4 categories.

Section A patterns specific to pharma

Several distinctive patterns:

1. Products-and-services breakdown — typically segmented by therapeutic area (cardiovascular, anti-diabetic, anti-infective, oncology, CNS) or by business segment (formulation vs API / intermediates vs CDMO / CRAMS vs consumer / OTC). The principal-services-by-turnover schedule frequently shows substantial concentration in two or three segments.
2. Operational locations — for entities with substantial manufacturing footprint, the Section A operations disclosure lists plants across multiple states (commonly Andhra Pradesh / Telangana, Gujarat, Himachal Pradesh, Sikkim, Maharashtra, Karnataka). Many entities supply the full plant register as an annexure.
3. Workforce structure — multi-tier: corporate / R&D / scientific personnel, plant management, permanent operators, contract operators, security and housekeeping outsourced labour. The mapping into BRSR’s employee / worker categorisation requires a documented internal table — see the BRSR Section A Pre-fill Workflow.
4. Subsidiary / group structure — listed pharma entities commonly have international subsidiaries (US generics, EU formulation entities, contract-research subsidiaries) and joint ventures for specific therapeutic areas or geographies. The boundary basis for BRSR (operational vs financial vs equity-share control) should be applied consistently with Ind AS 110 consolidation and the SEBI December 2024 Industry Standards methodology guidance.
5. CSR spend — Section 135 of the Companies Act 2013 typically applies to large listed pharma entities; the Section A CSR block is usually substantive. Pharma CSR commonly anchors on healthcare-access, healthcare-infrastructure, and education themes adjacent to the entity’s core competence.

How Batchwise fits

Batchwise coordinates BRSR Core Assurance for listed pharma entities through its partner CA firm network. The BRSR Core sign-off is delivered under partner CA firm letterhead and DSC; Batchwise handles the operational layer — buyer onboarding, evidence ingestion via the document portal, partner CA firm assignment, status tracking, and a 72-hour SLA on the coordinated end-to-end. For pharma entities that also need ISAE 3410 GHG verification (typically for the Scope 1 + 2 GHG inventory presented under BRSR Principle 6 or for separately published carbon-disclosure reports), Batchwise coordinates that engagement separately under the same partner-CA-firm model.

See also: Document and Evidence Requirements for the artifacts the assurance provider expects, and Materiality Assessment Walkthrough for the upstream scoping step that drives which Core attributes the engagement focuses on.